Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia
This trial will be conducted in three parts. In Part A and Part B, eligible patients will receive RO7283420 once every three weeks on Cycle 1, Day 1 for up to six cycles of treatment, with a starting dose of either 0.15mg (Part A) or at the highest dose administered in Part A (Part B) to determine the recommended phase 2 dose (RP2D). Patients in Part C will receive the RP2D identified for RO7283420.